Trial Profile
A real world study of the adjuvant therapy of apatinib mesylate tablet for high-risk postoperative recurrence of hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 29 Sep 2018 Status changed from not yet recruiting to recruiting.
- 10 Sep 2018 New trial record